【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the World Market for Cancer-Treating Drugs
1.2 Why You Should Read This Report
1.3 How This Study Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who is this Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Cancer Treatments
2.1 The Physiology of Cancer – Causes and Effects
2.1.1 Uncontrolled Growth
2.1.2 Dedifferentiation
2.1.3 Invasiveness and Metastasis
2.1.4 Causes of Cancer
2.2 The Incidence and Prevalence of Cancer – Trends in the World
2.2.1 Incidence
2.2.2 Mortality
2.2.3 Survival – Improving Odds
2.2.3.1 The Developed World
2.2.3.2 The Developing World – More Must Be Done
2.3 Treating Tumours – How Can We Fight Back?
2.3.1 Chemotherapy – The Traditional Treatment
2.3.2 Hormone Therapies
2.3.3 Immunotherapy – A Magic Bullet?
2.3.3.1 Monoclonal Antibodies (mAbs)
2.3.3.2 Cancer Vaccines
2.3.3.3 Non-Specific Immunotherapies
2.3.4 Targeted Therapies
2.3.5 Differentiating Agents
3. The World Anti-Cancer Drugs Market, 2015-2025
3.1 Global Anti-Cancer Drugs Market Forecast, 2015-2025
3.2 The Domination of Immunotherapies in 2014
3.3 The Immunotherapy Anti-Cancer Drugs Market Forecast, 2015-2025 – The Fastest Growing Segment
3.4 The Chemotherapy Anti-Cancer Drugs Market Forecast, 2015-2025
3.5 The Targeted Therapy Anti-Cancer Drugs Market Forecast, 2015-2025 – A Move towards Personalisation
3.6 The Hormone Therapy Anti-Cancer Drugs Market Forecast, 2015-2025
4. Leading National Markets, 2015-2025
4.1 Anti-Cancer Drugs – Leading Markets, 2014
4.2 The US Anti-Cancer Drugs Market, 2015-2025 – Continued Leadership or Terminal Decline?
4.2.1 The US Anti-Cancer Drugs Market, 2014
4.2.2 The US Anti-Cancer Drugs Market Forecast – A Matured Approach
4.2.3 The Effect of Regulations on the US Market
4.3 The Japanese Anti-Cancer Drugs Market, 2015-2025 – Still Steady?
4.4 The EU5 Anti-Cancer Drugs Market, 2015-2025 – Rivalling the US in Importance
4.5 The BRIC Countries Anti-Cancer Drugs Market, 2015-2025 – Awakening Sleeping Giants?
4.5.1 The Brazilian Anti-Cancer Drugs Market, 2015-2025 – Expansion of the Middle Class
4.5.2 The Russian Anti-Cancer Drugs Market, 2015-2025 – Rising Cancer Rates Stimulate Revenue Increases
4.5.3 The Indian Anti-Cancer Drugs Market, 2015-2025 – Lucrative Opportunity for Growth
4.5.4 The Chinese Anti-Cancer Drugs Market, 2015-2025 – Can it Reach its Potential?
5. The Top 25 Anti-Cancer Drugs: Revenue Forecasts, 2015-2025
5.1 Avastin (Roche) – The World Market Leader
5.1.1 Avastin Revenue, 2011-2014 – Mixed Growth
5.1.2 Avastin Revenue Forecast – Still No.1?
5.2 Herceptin (Roche) – The Looming Impact of Patent Expiry
5.2.1 Herceptin Revenue, 2011-2014 – Still Rising
5.2.2 Herceptin Revenue Forecast – Generic Erosion
5.3 Rituxan/MabThera (Roche) – Slowing Growth
5.3.1 Rituxan Revenue, 2011-2014 – Still Strong
5.3.2 Rituxan Revenue Forecast – Heading for a Decline
5.4 Gleevec/Glivec (Novartis) – The Maturation of a Blockbuster
5.4.1 Glivec Revenue, 2011-2014
5.4.2 Glivec Revenue Forecast – What Does the Future Hold?
5.5 Revlimid (Celgene) – Celgene’s Top Revenue Generator
5.5.1 Revlimid Revenue, 2011-2014 – Still on the Rise
5.5.2 Revlimid Revenue Forecast – A Long Term Leader?
5.6 Alimta (Eli Lilly) – A Slow Decline?
5.6.1 Alimta Revenue, 2011-2014
5.6.2 Alimta Revenue Forecast – Revenue Erosion Looming
5.7 Velcade (J&J/Takeda) – Rising Steadily
5.7.1 Velcade Revenue, 2011-2014
5.7.2 Velcade Revenue Forecast – A Dependable Sales Generator
5.8 Erbitux (Bristol-Myers Squibb/Merck KGaA) – Facing Tough Competition
5.8.1 Erbitux Revenue, 2011-2014
5.8.2 Erbitux Revenue Forecast – No More Growth?
5.9 Gardasil (Merck & Co.) – The Rise of Prevention
5.9.1 Gardasil Revenue, 2011-2014
5.9.2 Gardasil Revenue Forecast – Still Growing Strong
5.10 Zytiga (Johnson & Johnson)
5.10.1 Zytiga Revenue, 2011-2014 – The Rise of a New Drug
5.10.2 Zytiga Revenue Forecast
5.11 Xeloda (Roche) – Patent Exclusivity and the Future
5.11.1 Xeloda Revenue, 2011-2014 – The Impact of Combination Therapies
5.11.2 Xeloda Revenue Forecast – A Slippery Slope
5.12 Tarceva (Roche)
5.12.1 Tarceva Revenue, 2011-2014 – No Clear Pattern
5.12.2 Tarceva Revenue Forecast
5.13 Afinitor (Novartis) – A Targeted Approach
5.13.1 Afinitor Revenue, 2011-2014 – Growing Fast
5.13.2 Afinitor Revenue Forecast
5.14 Sprycel (Bristol-Myers Squibb)
5.14.1 Sprycel Revenue, 2011-2014
5.14.2 Sprycel Revenue Forecast – How Long Will the Growth Last?
5.15 Tasigna (Novartis) – Moving Up
5.15.1 Tasigna Revenue, 2011-2014
5.15.2 Tasigna Revenue Forecast – A Multi-Billion Dollar Product?
5.16. Sutent (Pfizer)
5.16.1 Sutent Revenue, 2011-2014
5.16.2 Sutent Revenue Forecast – No More Growth
5.17 Nexavar (Bayer/Onyx Pharmaceuticals)
5.17.1 Nexavar Revenue, 2011-2014 – The Effect of Regional Sales
5.17.2 Nexavar Revenue Forecast – A Promising Start
5.18 Xgeva (Amgen)
5.18.1 Xgeva Revenue, 2011-2014 – The Impact of New Indications
5.18.2 Xgeva Revenue Forecast
5.19 Zoladex (AstraZeneca)
5.19.1 Zoladex Revenue, 2011-2014
5.19.2 Zoladex Revenue Forecast
5.20 Yervoy (Bristol-Myers Squibb) – Starting to Make its Mark
5.20.1 Yervoy Revenue, 2011-2014
5.20.2 Yervoy Revenue Forecast – Will Sales Keep Growing?
5.21 Vidaza (Celgene) – What Growth Potential?
5.21.1 Vidaza Revenue, 2011-2014
5.21.2 Vidaza Revenue Forecast – Generic Impact?
5.22 Treanda (Teva Pharmaceuticals)
5.22.1 Treanda Revenue, 2011-2014
5.22.2 Treanda Revenue Forecast – Stalled Growth?
5.23 Temodar/Temodal (Merck & Co.) – Falling off the Cliff?
5.23.1 Temodar/Temodal Revenue, 2011-2014
5.23.2 Temodar/Temodal Revenue Forecast
5.24 Faslodex (AstraZeneca) – The Counterpart to Zoladex
5.24.1 Faslodex Revenue, 2011-2014
5.24.2 Faslodex Revenue Forecast
5.25 Abraxane (Celgene) – Beginning the Climb
5.25.1 Abraxane Revenue, 2011-2014
5.25.2 Abraxane Revenue Forecast
6. Drugs Approved in 2014-2015: Potential Future Blockbusters
6.1 Approved Treatments in 2015
6.1.1 Farydak (panobinostat/Novartis)
6.1.2 Ibrance (palbociclib/Pfizer)
6.1.3 Lenvima (lenvatinib mesylate/Eisai)
6.1.4 Opdivo (nivolumab/Bristol-Myers Squibb)
6.1.5 Unituxin (dinutuximab/United Therapeutics)
6.2 Approved Treatments in 2014
6.2.1 Beleodaq (belinostat/Spectrum Pharmaceuticals)
6.2.2 Blincyto (blinatumomab/Amgen)
6.2.3 Cyramza (ramucirumab/Eli Lilly): A Breakthrough for Gastric Cancer?
6.2.4 Imbruvica (ibrutinib/Pharmacyclics)
6.2.5 Keytruda (pembrolizumab/Merck)
6.2.6 Lynparza (olaparib/AstraZeneca)
6.2.7 Zydelig (idelalisib/Gilead)
6.2.8 Zykadia (ceritinib/Novartis) – The Rise of Kinase Inhibitors
6.2.9 Tafinlar (Novartis) – A Partner for Mekinist
6.2.10 Kadycla (Roche) – A Future Star
7. Leading Companies for Cancer Treatments, 2014
7.1 Anti-Cancer Drug Market Dominated by Seven Companies
7.2 Roche – Leader of the Pack
7.2.1 Oncology Pipeline – Investment in the Future
7.2.2 Roche’s Future Direction in Cancer Treatment
7.3 Novartis – Closing the Gap on Roche
7.3.1 Oncology R&D Pipeline – What’s the Potential?
7.3.2 Future Directions for Novartis
7.4 Celgene – A Pressing Need to Diversify?
7.4.1 Celgene’s Oncology R&D Pipeline – Safeguarding the Future
7.4.2 Future Directions for Celgene
7.5 Eli Lilly – Reliant on Alimta
7.5.1 Oncology R&D Pipeline – What Potential Exists?
7.5.2 The Future Direction of Eli Lilly
7.6 AstraZeneca – Climbing Up the Ladder
7.6.1 Oncology R&D Pipeline – Showing Promise
7.6.2 The Future Direction of AstraZeneca
7.7 Bristol-Myers Squibb
7.7.1 Oncology R&D Pipeline – What Potential Exists?
7.7.2 Future Direction of BMS
7.8 Merck &Co. – Prominent in Vaccines
7.8.1 Oncology R&D Pipeline – Greater Focus on Cancer
7.8.2 The Future Direction of Merck
7.9 Johnson & Johnson
7.9.1 Oncology J&J Pipeline – A Focus on Prostate Cancer Drugs
8. R&D Pipelines for Cancer Treatment
8.1 Breast Cancer Drugs under Development
8.1.1 Neratinib (Puma Pharmaceuticals)
8.1.2 Veliparib (Abbvie)
8.1.3 NeuVax (Galena Biopharma)
8.1.4 Entinostat (Syndax)
8.2 Prostate Cancer Drugs under Development
8.2.1 ODM-201 (Orion) – Jointly Developed with Bayer
8.2.2 Tasquinimod (Active Biotech)
8.2.3 EMD-525797 (EMD Serono)
8.2.4 PROSTVAC (Bavarian Nordic)
8.3 Lung Cancer Drugs under Development
8.3.1 RG7446 (Roche)
8.3.2 Nivolumab (Bristol-Myers Squibb)
8.3.3 MEDI4736 (AstraZeneca)
8.3.4 TG4010 (Transgene)
8.4 Colorectal Cancer Drugs under Development
8.4.1 Imprime PGG (Biothera)
8.4.2 Xilonix (Xbiotech)
8.4.3 HA-Irinotecan (Alchemia)
8.5 Cervical Cancer Drugs under Development
8.5.1 ADXS-HPV (Advaxis)
8.5.2 V503 (Merck & Co.)
8.5.3 VGX-3100 (Inovio Pharmaceuticals)
8.6 Stomach Cancer Drugs under Development
8.6.1 Rilotumumab (Amgen)
8.6.2 Onartuzumab (Roche)
8.6.3 Apatinib (Jiangsu Hengrui Medicine)
8.7 Liver Cancer Drugs under Development
8.7.1 Tivantinib (ArQule)
8.7.2 Lenvatinib (Eisai Co.)
8.7.3 Pexa-Vec (Jennerex Biotherapeutics)
8.7.4 Brivanib (Bristol-Myers Squibb)
8.7.5 Muparfostat (Progen Pharmaceuticals)
8.8 Ovarian Cancer Drugs under Development
8.8.1 Farletuzumab (Eisai)
8.8.2 Niraparib (TESARO)
8.8.3 Trebananib (Amgen)
8.9 Bladder Cancer Drugs under Development
8.9.1 Vesimune (Telormedix)
8.9.2 HS-410 (Heat Biologics)
8.9.3 EOquin (Allergan)
8.10 Non-Hodgkin’s Lymphoma Drugs under Development
8.10.1 Idelalisib (Gilead)
8.10.2 IPI-145 (Infinity Pharmaceuticals)
8.10.3 ABT-199 (AbbVie)
8.10.4 GS-9973 (Gilead)
8.11 Leukaemia Drugs under Development
8.11.1 Dinaciclib (Merck)
8.11.2 Sapacitabine (Cyclacel Pharmaceuticals)
8.11.3 Vosaroxin (Sunesis)
8.12 Kidney Cancer Drugs under Development
8.12.1 IMA901 (Immatics)
8.12.2 AGS-003 (Argos Therapeutics)
8.12.3 Nilovumab (Bristol-Myers Squibb)
8.12.4 TRC105 (Tracon Pharmaceuticals)
8.13 Pancreatic Cancer Drugs under Development
8.13.1 Algenpantucel-L (NewLink Genetics)
8.13.2 MM-398 (Merrimack)
8.13.3 MK-0752 (Merck & Co.)
9. Qualitative Analysis of the Anti-Cancer Drug Market 2015-2025
9.1 SWOT Analysis of the Anti-Cancer Drugs Market
9.1.1 Strengths of the Market
9.1.1.1 The Rising Incidence of Cancer
9.1.1.2 Ample Treatment Options Available
9.1.2 Weaknesses
9.1.2.1 The Challenges of Drug Development
9.1.2.2 The Complex Nature of Cancer
9.1.3 Opportunities in the Anti-Cancer Drugs Market
9.1.3.1 The Advancement of Research
9.1.3.2 A Shift Towards Personalisation
9.1.4 Threats Facing the Anti-Cancer Drugs Market
9.1.4.1 The Threat of Regulation
9.2 STEP Analysis of the Anti-Cancer Drugs Market
9.2.1 Social Factors: The Cost of Living Longer
9.2.2 Technological Developments: Making the Market Move Forward
9.2.3 Economic Pressure: Treatment’s Hefty Price Tag
9.2.4 Political Issues: Governmental Involvement in Treatment
10. Research Interviews from Our Survey
10.1 Dr Cesar M. Castro, Massachusetts General Hospital Cancer Center and Center for Systems Biology, Boston
10.1.1 D3 Enables Point-of-care and Real Time Testing of Tumours
10.1.2 The Use of D3 to Detect Cancer
10.1.3 D3 – Speed, Ease of Use, Low Cost and Accurate
10.1.4 D3 – Possibility of Detecting Various Types of Cancer
10.1.5 Further Development and Refinement
10.2 Dr Silvia Paddock, Senior Associate, Rose Li and Associates, Inc.
10.2.1 PACE CII – Meeting the Needs of a Diverse Range of Stakeholders
10.2.2 PACE CII – Main Components
10.2.3 PACE CII – a Flexible Framework for Objective Assessments of Progress
10.2.4 Value of Cancer Treatments – Dynamic and Complex
10.2.5 Multiple Stakeholders – Shared Perspectives on Treatment Goals?
10.2.6 Free Access to Database and Tool
11. Conclusions of the Study
11.1 The Top 25 Drugs in the Cancer Treatment Market
11.2 Immunotherapies – The Future of the Market
11.3 Patent Expiries and the Impact of Biosimilars
11.4 The US – Still the Largest National Market
11.5 China and Brazil Will Lead the Emerging Markets
11.6 Treatment – It’s Personal
11.7 The Anti-Cancer Drug Pipeline Remains Strong
11.8 Concluding Remarks
【レポート販売概要】
■ タイトル：がん治療薬の世界市場：企業動向、治療、研究開発、市場予測■ 英文：World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025
■ 発行日：2015年7月
■ 調査会社：visiongain
■ 商品コード：VGAIN5081912
■ 調査対象地域：グローバル
- ハイバリア性パウチの世界市場2016-2020About Packaging Packaging has become an integral part in the supply chain of any industry. This increased the demand for packaging in different sectors such as food and beverages, agriculture, healthcare, and construction, which have introduced innovative packaging materials and designs. In the past two decades, the packaging industry has seen a huge transformation in terms of innovation. From sim …
- 呼吸ケア装置の世界市場予測（～2024年）“High prevalence of respiratory diseases as a result of the rapid growth in the global geriatric population is expected to drive the growth of the respiratory care devices market.” The respiratory care devices market is projected to reach USD 31.8 billion by 2024 from USD 20.6 billion in 2019, at a CAGR of 9.1%. The rapid growth in the global geriatric population, rising incidence of chronic disea …
- 世界の陸上移動無線(LMR)システム市場動向（2012-2016）TechNavio's analysts forecast the Global Land Mobile Radio (LMR) System market to grow at a CAGR of 11.7 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for efficient mission critical operations. The Global LMR System market has also been witnessing increasing shipment of integrated devices that support both LMR and LTE function …
- モバイルバイオメトリクス（生体認証）の世界市場：指紋認証、音声認証、顔認証About the Mobile Biometrics Market Data security is a serious concern for government organizations, enterprises, and individuals. Identity badges, numeric keypads, and PINs were the most popular devices used to prevent unauthorized access to sensitive data and assets. Advances in technology led to the introduction of two-factor authentication, which allows access on the basis of hardware devices a …
- PIM（粉末射出成形）の世界市場：金属粉末射出成型（MIM）、セラミックス粉末射出成形（CIM）About PIM PIM is used during the manufacturing process of products, such as medical devices, aerospace components, and automotive components, through net-shaping technique. Powder (metal or ceramic) is injected into an injection molding machine and then molded into specific designs as per specifications. PIM is useful in manufacturing complex product components in high volume. TechNavio's analysts …
- 世界の主要ウェアラブル技術企業動向2014Wearable technology is the buzzword of 2014. A market that has existed for decades, however now microprocessors and MEMS are finally compact enough for the device category to reach fruition. In an environment heading towards a connected homes paradigm, the next step in our technological evolution is bringing control closer than arm’s reach. Wearables dominated 2014’s CES, with every major OEM cham …
- 組み込みコンピューターの世界市場2020-2024Global Embedded Computer Market 2020-2024 Technavio has been monitoring the global embedded computer market and it is poised to grow by USD 856.91 mn during 2020-2024, progressing at a CAGR of 5% during the forecast period. Our reports on embedded computer market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering arou …
- Italian Hospital Infectious Disease Testing Market 2014This new report from Venture Planning Group contains 887 pages, 72 tables, and presents a comprehensive analysis of the Italian hospital infectious disease testing market, including: Major issues pertaining to the Italian hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.&n …
- DeeThree Exploration Ltd.：石油・ガスの開発・生産動向及びコスト分析- Q1, 2013DeeThree Exploration Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis - Q1, 2013 Summary DeeThree Exploration Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essentia …
- 抗核抗体（ANA）検査の世界市場予測（～2021年）：試薬＆検定キット、装置、ソフトウェア、サービスThe global Antinuclear Antibody Test market is expected to reach USD 1,476.1 Million by 2021 from USD 823.5 Million in 2016, at a CAGR of 12.4%. This market is segmented based on products, diseases, techniques, end users, and regions. On the basis of products, the ANA testing market is segmented into assay kits & reagents, systems, and software & services. The assay kits & reagents segment is expe …
- バイオ外科手術用製品の世界市場：外科用接着剤、止血薬、軟部組織パッチ、合成メッシュ、癒着防止材料、移植骨代用材Biosurgery products are used to aid surgeries and repair weakened and damaged tissues and bones of a body. The biosurgery market is majorly driven by the rising number of surgeries owing to the increasing rate of obesity and other lifestyle disorders, increasing participation in sports leading to sports-related injuries, and growing aging population. However, lack of reimbursement for these produc …
- 世界におけるタッチスクリーン向けのハプティック技術市場The haptic technology has been explored for human computer interaction since long. It became popular and well known in the form of vibrating alarms in cell phones. Haptic sensing is considered to be more direct as compared to the other senses used in human computer interaction like audition and vision. The touch sensations are created by a haptic actuator embedded in the device. Some of the major …
- スマート水管理市場（グローバル市場予測及び分析）Utilities and governments across the globe are pressed with meeting the increasing demand of quality water and maintaining the aging infrastructure of water networks. Non-Revenue Water (NRW) accounts for a significant loss to water utilities financially due to leaks, theft, and metering errors. Smart Water Management (SWM) solutions are vital to water utilities facing such issues. SWM allows for s …
- タラゴンの世界市場2019-2023120 Pages, November 2018 About this market The growing demand for products containing multiple herbs is identified as one of the key trends that will gain traction in the market for the next four years. Multi-herb formulas benefits heart helps liver problems, digestion, and improves the immune function. Technavio’s analysts have predicted that the tarragon market will register a CAGR of over 9% by …
- 作物保護化学薬品の世界市場：除草剤、殺虫剤、殺菌剤The crop protection chemicals market is projected to grow at a CAGR of 5.15% to reach USD 70.57 Billion by 2021. The market growth is driven by the rising need for food security for the growing population, advancement in farming practices and technologies and heavy crop loss due to pest infestations. The market is further driven by factors such as increasing demand for biopesticides along with inc …
